5 May 2023
SHARE NOW
ATW
Cell Therapy
Finance & Investment
Gene Therapy
Scaling Up
Strategy
This Briefing from Advanced Therapies Week 2023 focusses on the delivery of a fully funded, third party biotech facility over an expedited timeline compared to traditional build construction methods.
During this session, Tony Wells (CEO) and Matthew Toomey (Business Development Director) from Merit are joined by Piers Slater, CEO at Reef Group, Will Rohleder, Director at Reef Group, Miranda Neville, VP of Global Operations & Delivery at Autolus and Olivia Drew, Portfolio Manager at UBS UK Life Sciences.
This Briefing was presented at Advanced Therapies Week 2023, in partnership with Merit.
More like this
20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry
Lee Buckler, SVP Advanced Therapies, Blood Centers of America, Advanced Therapies Network, reflects on two decades of working within the advanced therapies industry as Phacilitate celebrates 20 years of operating in the field.
4 December 2023
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
Oxford Biomedica Acquires ABL Europe from Institut Mérieux
6 December 2023
Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome
Two female pediatric patients with Rett syndrome were the first children worldwide to receive the promising treatment with Neurogene’s lead gene therapy product.
5 December 2023
Discover more like this
